Is Now a Good Opportunity to Include Thermo Fisher Stock in Your Investment Portfolio?

Thermo Fisher Scientific: Growth Strategies and Market Outlook

Thermo Fisher Scientific Inc. (TMO) continues to pursue long-term expansion through a series of targeted acquisitions. The company’s performance is also supported by robust demand across its core markets. However, challenges such as currency fluctuations and intense industry competition remain areas of concern for the business.

Over the past year, TMO shares have declined by 2.4%, while the broader medical products industry dropped 4.3%. In contrast, the S&P 500 index saw a gain of 21.9% during this period.

With a market value of $192.62 billion, Thermo Fisher stands out in the medical and laboratory equipment sector. The company’s earnings yield is 4.8%, outperforming the industry average of -0.7%. Notably, TMO has exceeded earnings expectations in each of the last four quarters, with an average positive surprise of 2.8%.

Key Drivers for Thermo Fisher

Expanding Market Presence: Thermo Fisher’s biosciences and bioproduction divisions have recently increased their production capabilities to address global vaccine needs. In the fourth quarter of 2025, the Pharma and Biotech segment achieved high single-digit growth, largely due to strong results in bioproduction and the research and safety market channel.

For the full year 2025, the Industrial and Applied segment benefited from solid performance in research and safety, as well as ongoing growth in electron microscopy. The Diagnostics and Healthcare segment saw notable gains in Specialty Diagnostics, with steady contributions from transplant diagnostics and immunodiagnostics, resulting in flat overall growth for the year.

Strategic Acquisitions Fueling Expansion: Thermo Fisher’s growth strategy centers on acquiring complementary businesses and technologies. In 2025, the company allocated about $16.5 billion for investments, including $13 billion dedicated to mergers and acquisitions. These moves are expected to generate $125 million in adjusted operating income synergies over the next five years, driven by both revenue and cost improvements.

Among recent deals, Thermo Fisher agreed in October 2025 to purchase Clario Holdings, Inc.—a leader in clinical trial endpoint data solutions—for $8.875 billion in cash. This acquisition is projected to add approximately $0.45 to adjusted EPS within the first year. In September 2025, the company finalized its $4.1 billion acquisition of Solventum’s Purification & Filtration business, which now operates within the Life Sciences Solutions segment.

Challenges Facing Thermo Fisher

Currency Risks: A significant portion of Thermo Fisher’s revenue comes from international markets, making the company vulnerable to exchange rate volatility. Fluctuations in currency values can impact reported sales and profits when converted to U.S. dollars for financial reporting.

As the company’s global sales increase, the influence of currency movements on financial outcomes becomes more pronounced. While foreign exchange provided a 1% year-over-year boost to sales in the fourth quarter of 2025, any reversal in currency trends could quickly impact future growth.

Competitive Landscape: Thermo Fisher operates in a highly competitive environment, facing rivals ranging from large manufacturers to third-party distributors. The need to keep pace with technological advancements and evolving customer requirements demands ongoing investment in research and development.

Analyst Estimates for TMO

According to Zacks, the consensus estimate for Thermo Fisher’s 2026 earnings per share remains steady at $24.66 over the past month.

Projected revenue for 2026 is $46.75 billion, representing a 4.9% increase compared to the previous year’s results.

Top Alternatives in the Medical Sector

• Phibro Animal Health (PAHC): With an earnings yield of 5.5%—well above the industry average of 2.5%—Phibro has outperformed expectations in each of the last four quarters, averaging a 20.2% earnings surprise. The company’s shares have soared 117.5% over the past year, while the industry declined by 15.1%. PAHC currently holds a Zacks Rank #1 (Strong Buy).
• Envista (NVST): Also rated Zacks Rank #1, Envista boasts a 4.8% earnings yield compared to the industry’s 2.5%. The company’s stock has climbed 54% in the past year, and it has beaten earnings estimates in each of the last four quarters, with an average surprise of 16.4%.
• Align Technology (ALGN): Currently holding a Zacks Rank #2 (Buy), Align Technology is projected to achieve long-term earnings growth of 10.1%, outpacing the industry’s 9.1%. The company’s shares have increased 7.5% over the past year, compared to the industry’s 22% gain. ALGN exceeded earnings estimates in three of the last four quarters, with an average surprise of 6.2%.

Featured Stock Picks from Zacks

Zacks’ research team has identified five stocks with the potential to double in value in the coming months. Among these, Director of Research Sheraz Mian highlights a lesser-known satellite communications company poised for significant growth as the space industry expands toward a trillion-dollar market. Analysts anticipate a major revenue surge for this firm in 2025. While not every top pick achieves such results, this company could outperform previous Zacks selections like Hims & Hers Health, which rose over 200%.

Further Reading and Reports